IBL News | New York
Moderna, Inc., (Nasdaq: MRNA) announced the launch of its Artificial Intelligence (AI) Academy in partnership with Carnegie Mellon University (CMU).
With its AI Academy, the well-known biotechnology company intends to educate its employees on AI and machine learning capabilities and skills.
This program will focus on data quality and data visualization, statistical thinking and models, machine learning algorithms, and AI ethics.
Classes will be both in-personas and online. The AI Academy will use the CMU-home-developed learning platform called ISLE (Integrated Statistics Learning Environment).
Moderna will launch the program this week with its first cohort of students. In early 2022, will be the full rollout.
The company’s goal is to identify and integrate these technologies into “every Moderna system and process to bring mRNA medicines to patients.”
The Cambridge, Massachusetts-based biopharmaceutical firm — which is pioneering messenger RNA (mRNA) therapeutics and vaccines, “attributes its speed in part to the incorporation of digital technologies,” said Stéphane Bancel, CEO of Moderna.
“We believe AI is a key enabler of our ability to build the best version of Moderna now and into the future. This AI academy will enable us to make AI part of the company’s ways of working, part of our DNA. We look forward to driving this with Carnegie Mellon’s team.”
To design and deliver Moderna’s AI Academy, CMU’s Department of Statistics & Data Science, a part of the Dietrich College of Humanities and Social Sciences, and the Tepper School of Business are collaborating with professors across the university.
